Urogen Pharma (URGN) Competitors

Lantheus (NASDAQ:LNTH) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Which has more volatility and risk, LNTH or URGN?

Lantheus has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Which has better valuation & earnings, LNTH or URGN?

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.52B	2.60	$312.44M	$3.76	15.48
Urogen Pharma	$91.87M	9.79	-$126.87M	-$3.32	-5.86

Do institutionals & insiders have more ownership in LNTH or URGN?

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 1.5% of Lantheus shares are owned by insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is LNTH or URGN more profitable?

Lantheus has a net margin of 17.82% compared to Urogen Pharma's net margin of -164.44%. Lantheus' return on equity of 34.06% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.82%	34.06%	19.10%
Urogen Pharma	-164.44%	-97,487.15%	-59.38%

Do analysts rate LNTH or URGN?

Lantheus currently has a consensus price target of $105.50, indicating a potential upside of 81.24%. Urogen Pharma has a consensus price target of $32.00, indicating a potential upside of 64.61%. Given Lantheus' higher possible upside, research analysts clearly believe Lantheus is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Urogen Pharma	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media favor LNTH or URGN?

In the previous week, Lantheus had 4 more articles in the media than Urogen Pharma. MarketBeat recorded 14 mentions for Lantheus and 10 mentions for Urogen Pharma. Lantheus' average media sentiment score of 0.55 beat Urogen Pharma's score of 0.34 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantheus beats Urogen Pharma on 11 of the 17 factors compared between the two stocks.